Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats

[1]  B. Riggs,et al.  Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women , 1999, Psychoneuroendocrinology.

[2]  C Labrie,et al.  Expression and neuropeptidergic characterization of estrogen receptors (ERalpha and ERbeta) throughout the rat brain: anatomical evidence of distinct roles of each subtype. , 1998, Journal of neurobiology.

[3]  D. Dorsa,et al.  Transcriptional Effects of Estrogen on Neuronal Neurotensin Gene Expression Involve cAMP/Protein Kinase A-Dependent Signaling Mechanisms , 1998, The Journal of Neuroscience.

[4]  J. Gustafsson,et al.  Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. , 1998, Molecular pharmacology.

[5]  L. Kuller,et al.  Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. , 1998, JAMA.

[6]  G. Mor,et al.  Raloxifene Induces Neurite Outgrowth in, Estrogen Receptor Positive PC 12 Cells , 1998, Menopause.

[7]  H. Bryant,et al.  Selective Estrogen Receptor Modulators: An Alternative to Hormone Replacement Therapy , 1998, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[8]  C. Christiansen,et al.  Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. , 1997, The New England journal of medicine.

[9]  I. Merchenthaler,et al.  Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: an in situ hybridization study. , 1997, Endocrinology.

[10]  M. Rice,et al.  Estrogen replacement therapy and cognitive function in postmenopausal women without dementia. , 1997, The American journal of medicine.

[11]  J. Simpkins,et al.  Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease. , 1997, The American journal of medicine.

[12]  L. Schneider,et al.  Combined Tacrine and Estrogen Replacement Therapy in Patients with Alzheimer's Disease a, b , 1997, Annals of the New York Academy of Sciences.

[13]  D. Witt,et al.  Controversies Surrounding Estrogen Use in Postmenopausal Women , 1997, The Annals of pharmacotherapy.

[14]  R. Gibbs.  Effects of estrogen on basal forebrain cholinergic neurons vary as a function of dose and duration of treatment , 1997, Brain Research.

[15]  J. Muir.  Acetylcholine, Aging, and Alzheimer's Disease , 1997, Pharmacology, Biochemistry and Behavior.

[16]  N. Demura,et al.  SDZ ENA 713 facilitates central cholinergic function and ameliorates spatial memory impairment in rats , 1997, Behavioural Brain Research.

[17]  E. Barrett,et al.  Neurotrophin Effects on Survival and Expression of Cholinergic Properties in Cultured Rat Septal Neurons under Normal and Stress Conditions , 1996, The Journal of Neuroscience.

[18]  Yaakov Stern,et al.  Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease , 1996, The Lancet.

[19]  H. Bryant,et al.  Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  A. Figer,et al.  Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients. , 1996, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[21]  C. Singer,et al.  The effects of ovariectomy and estrogen replacement on trkA and choline acetyltransferase mRNA expression in the basal forebrain of the adult female Sprague-Dawley rat , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  J. Simpkins,et al.  The effect of ovariectomy and estradiol replacement on brain-derived neurotrophic factor messenger ribonucleic acid expression in cortical and hippocampal brain regions of female Sprague-Dawley rats. , 1995, Endocrinology.

[23]  H. Honjo,et al.  Senile dementia-Alzheimer's type and estrogen. , 1995, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[24]  D. Ciocca,et al.  Estrogen receptors in human nontarget tissues: biological and clinical implications. , 1995, Endocrine reviews.

[25]  D. Pfaff,et al.  Effects of Estrogen Replacement on the Relative Levels of Choline Acetyltransferase, trkA, and Nerve Growth Factor Messenger RNAs in the Basal Forebrain and Hippocampal Formation of Adult Rats , 1994, Experimental Neurology.

[26]  N. Hagino,et al.  Evaluation of estrogen treatment in female patients with dementia of the Alzheimer type. , 1994, Endocrine journal.

[27]  V. Henderson,et al.  Estrogen deficiency and risk of Alzheimer's disease in women. , 1994, American journal of epidemiology.

[28]  W. Millard,et al.  Ovarian steroid deprivation results in a reversible learning impairment and compromised cholinergic function in female Sprague-Dawley rats , 1994, Brain Research.

[29]  Bruce S. McEwen,et al.  Estradiol and progesterone regulate neuronal structure and synaptic connectivity in adult as well as developing brain , 1994, Experimental Gerontology.

[30]  J L McGaugh,et al.  The role of interactions between the cholinergic system and other neuromodulatory systems in learing and memory , 1991, Synapse.

[31]  V. Luine.  Estradiol increases choline acetyltransferase activity in specific basal forebrain nuclei and projection areas of female rats , 1985, Experimental Neurology.

[32]  C. D. Jones,et al.  Antiestrogens. 2. Structure-activity studies in a series of 3-aroyl-2-arylbenzo[b]thiophene derivatives leading to [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl] [4-[2-(1-piperidinyl)ethoxy]-phenyl]methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal in , 1984, Journal of medicinal chemistry.

[33]  R. Bartus,et al.  Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat , 1983, Pharmacology Biochemistry and Behavior.

[34]  K. Grandien,et al.  Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors a and b , 1997 .

[35]  B. Mitlak,et al.  In search of optimal long-term female hormone replacement: the potential of selective estrogen receptor modulators. , 1997, Hormone research.

[36]  D. Williams,et al.  Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. , 1994, The Journal of clinical investigation.

[37]  L. Green,et al.  Non-steroidal antioestrogens--receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. , 1984, Journal of steroid biochemistry.

[38]  D. Bowen,et al.  Chemical pathology of this organic dementias. II. Quantitative estimation of cellular changes in post-mortem brains. , 1977, Brain : a journal of neurology.